救济治疗机构宣布,RLF-OD032的PKU治疗结果大有希望,类似于无水管理KUVAN粉。 Relief Therapeutics announces promising PKU treatment results for RLF-OD032, similar to KUVAN® powder with water-free administration.
Relief Therapeutics Holding SA 宣布其 RLF-OD032 的概念验证研究取得了可喜的结果，RLF-OD032 是一种旨在治疗苯丙酮尿症 （PKU） 的盐酸沙丙蝶呤浓缩液体制剂。 Relief Therapeutics Holding SA announced promising results from its proof-of-concept study for RLF-OD032, a concentrated liquid formulation of sapropterin dihydrochloride aimed at treating phenylketonuria (PKU). 研究显示,RLF-OD032的功效与KUVAN粉粉类似,其额外好处是没有水的施用,提高了病人的方便性。 The study showed RLF-OD032's effectiveness similar to KUVAN® powder, with the added benefit of being administered without water, enhancing patient convenience. 该公司计划在美国提交NDA材料时进行关键的生物等同试验。 The company plans to proceed with a pivotal bioequivalence trial as part of its NDA submission in the U.S.